# TYBR Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tybr-health

- Industry: Medical Devices & Equipment
- Headquarters: Houston, US
- Website: www.tybrhealth.com/
- Total disclosed funding: $14M
- Latest round: Series A (Jul 9, 2026)
- Investors on record: 5

## About

Based in Houston, US, founded in 2020, TYBR Health specializes in developing medical solutions that assist in post-operative tendon recovery. The company was co-founded by Tim Keane (CEO as of 2026) and Alex Smith. In July 2026, TYBR Health, Inc. raised USD 14.35 million in series A funding co-led by Mutual Capital Partners and Vensana Capital, with participation from Ariel Southeast Angel Partners, Asymmetry Ventures and Neovate Capital Partners.

TYBR Health specializes in the development and commercialization of the B3 GEL™ System, a proprietary product designed to enhance post-operative tendon mobility following surgical procedures. The B3 GEL™ System utilizes an ECM-based gel to create a protective environment around healing tendons and ligaments, addressing issues related to scar formation and mobility limitations affecting up to 40% of tendon repair patients. Targeted primarily at orthopedic surgeons, rehabilitation specialists, and clinics involved in tendon repair, the product is marketed in the United States and regions with advanced healthcare infrastructures emphasizing surgical innovation and patient recovery.

TYBR Health generates revenue through the sale of its flagship B3 GEL™ System primarily to healthcare providers, including hospitals and surgical centers. Transactions occur on a B2B basis, with healthcare institutions purchasing the product for surgical use. Pricing structures are based on individual product sales, with a potential for volume-based agreements depending on client needs. The company's revenue model includes direct sales and partnerships with distributors specializing in surgical products, relying on clinical evidence to drive repeat business and establish long-term client relationships.

The company plans to use the July 2026 funding to broaden product applications, conduct orthopedic clinical studies, and increase surgeon access to its solutions.

## Funding rounds

- Series A, Jul 9, 2026, $14M — Mutual Capital Partners, Ariel Southeast Angel Partners, Vensana Capital, Asymmetry Ventures, Neovate Capital Partners

## Investors

- Mutual Capital Partners (https://capitalatlas.ai/funds/mutual-capital-partners) — Series A
- Ariel Southeast Angel Partners (https://capitalatlas.ai/funds/ariel-southeast-angel-partners) — Series A
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series A
- Asymmetry Ventures (https://capitalatlas.ai/funds/asymmetry-ventures) — Series A
- Neovate Capital Partners (https://capitalatlas.ai/funds/neovate-capital-partners) — Series A